| Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group PY Wen, DR Macdonald, DA Reardon, TF Cloughesy, AG Sorensen, ... Journal of clinical oncology 28 (11), 1963-1972, 2010 | 4081 | 2010 |
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma HS Friedman, MD Prados, PY Wen, T Mikkelsen, D Schiff, LE Abrey, ... Journal of clinical oncology 27 (28), 4733-4740, 2009 | 2958 | 2009 |
| Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma OL Chinot, W Wick, W Mason, R Henriksson, F Saran, R Nishikawa, ... New England Journal of Medicine 370 (8), 709-722, 2014 | 2698 | 2014 |
| Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors IK Mellinghoff, MY Wang, I Vivanco, DA Haas-Kogan, S Zhu, EQ Dia, ... New England Journal of Medicine 353 (19), 2012-2024, 2005 | 1731 | 2005 |
| Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma R Beroukhim, G Getz, L Nghiemphu, J Barretina, T Hsueh, D Linhart, ... Proceedings of the National Academy of Sciences 104 (50), 20007-20012, 2007 | 1245 | 2007 |
| High-throughput oncogene mutation profiling in human cancer RK Thomas, AC Baker, RM DeBiasi, W Winckler, T LaFramboise, WM Lin, ... Nature genetics 39 (3), 347-351, 2007 | 1169 | 2007 |
| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ... Nature medicine 25 (3), 477-486, 2019 | 1160 | 2019 |
| Gene expression profiling of gliomas strongly predicts survival WA Freije, FE Castro-Vargas, Z Fang, S Horvath, T Cloughesy, LM Liau, ... Cancer research 64 (18), 6503-6510, 2004 | 885 | 2004 |
| Standards of care for treatment of recurrent glioblastoma—are we there yet? M Weller, T Cloughesy, JR Perry, W Wick Neuro-oncology 15 (1), 4-27, 2013 | 835 | 2013 |
| Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions PY Wen, M Weller, EQ Lee, BM Alexander, JS Barnholtz-Sloan, ... Neuro-oncology 22 (8), 1073-1113, 2020 | 799 | 2020 |
| Adult glioblastoma BM Alexander, TF Cloughesy Journal of Clinical Oncology 35 (21), 2402-2409, 2017 | 799 | 2017 |
| Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target S Horvath, B Zhang, M Carlson, KV Lu, S Zhu, RM Felciano, MF Laurance, ... Proceedings of the National Academy of Sciences 103 (46), 17402-17407, 2006 | 750 | 2006 |
| Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma TF Cloughesy, K Yoshimoto, P Nghiemphu, K Brown, J Dang, S Zhu, ... PLoS medicine 5 (1), e8, 2008 | 674 | 2008 |
| Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials BM Ellingson, M Bendszus, J Boxerman, D Barboriak, BJ Erickson, ... Neuro-oncology 17 (9), 1188-1198, 2015 | 673 | 2015 |
| Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment LM Liau, RM Prins, SM Kiertscher, SK Odesa, TJ Kremen, AJ Giovannone, ... Clinical Cancer Research 11 (15), 5515-5525, 2005 | 634 | 2005 |
| Glioblastoma: from molecular pathology to targeted treatment TF Cloughesy, WK Cavenee, PS Mischel Annual review of pathology: mechanisms of disease 9 (1), 1-25, 2014 | 602 | 2014 |
| Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA DA Nathanson, B Gini, J Mottahedeh, K Visnyei, T Koga, G Gomez, ... Science 343 (6166), 72-76, 2014 | 596 | 2014 |
| Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme DA Reardon, KL Fink, T Mikkelsen, TF Cloughesy, A O'Neill, S Plotkin, ... Journal of clinical oncology 26 (34), 5610-5617, 2008 | 577 | 2008 |
| Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo G Choe, S Horvath, TF Cloughesy, K Crosby, D Seligson, A Palotie, ... Cancer research 63 (11), 2742-2746, 2003 | 573 | 2003 |
| Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme A Lai, A Tran, PL Nghiemphu, WB Pope, OE Solis, M Selch, E Filka, ... Journal of clinical oncology 29 (2), 142-148, 2011 | 562 | 2011 |
Whitney B. PopeProfessor of Radiology, David Geffen School of Medicine at UCLA在 mednet.ucla.edu 的电子邮件经过验证
